Awaiting development: Guidance and quality standards

Showing 281 to 290 of 336

Guidance and quality standards awaiting development
Title	Type
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]	Technology appraisal guidance
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]	Technology appraisal guidance
Tarlatamamb for treating small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Technologies for the rapid diagnosis of endometriosis	Health technology evaluation
Technologies to improve detection of endometrial cancer	Health technology evaluation
Technologies to support home monitoring of vision change in macular disease	Health technology evaluation
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]	Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound	Medical technologies guidance